Latest Commercialization News

Surefire Resources NL has announced a significant extension of gold mineralisation at its Yidby Gold Project, now exceeding 500 metres in strike length. The company’s recent drilling and metallurgical test work support plans for a low-cost heap leach operation.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

Emmerson Resources has announced a maiden Mineral Resource Estimate for its White Devil deposit, adding nearly 490,000 ounces of high-grade gold and expanding the Tennant Creek resource base by 130% to 866,000 ounces. This milestone sets the stage for accelerated development and potential reclassification of the deposit under the joint venture with Pan African Resources.

Boss Energy has declared commercial production effective January 1, 2025, reporting strong quarterly uranium output growth and a robust financial position. The company remains on track to deliver 850,000 pounds of U3O8 in FY2025 amid ongoing ramp-up and expansion initiatives.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Renascor Resources has marked significant progress in its Purified Spherical Graphite (PSG) demonstration plant development, securing a site and completing initial production runs ahead of commissioning in late 2025.

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

Lion Energy Limited reports significant progress in its green hydrogen project at Port of Brisbane and confirms major oil and gas prospects in Indonesia, setting the stage for future drilling and commercial development.

Anax Metals has confirmed the success of its scaled-up bioleaching technology, achieving copper recoveries of up to 80% and zinc recoveries exceeding 90%, reinforcing its strategic position in Pilbara's base metals sector.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

AVADA Group Limited reports a positive cash flow for Q4 2024, supported by increased collections and operational consolidation, even as government funding shifts delay project starts.

Arrow Minerals has secured $7 million through a well-supported placement to advance its flagship Niagara Bauxite and Simandou North Iron projects in Guinea, setting the stage for key resource milestones and development studies.